

Vita

Omar Moh'd Musa Ibrahim

o.ibrahim0@gmail.com

Date and Place of Birth

August 17 1977 Amman, Jordan

Education

Ph.D.	Pharmacotherapy and Outcomes Science	August 2012	Virginia Commonwealth University Richmond, VA
B.Sc.	Pharmacy	June 2000	University of Jordan Amman, Jordan

Professional Experience

Assistant Professor, Alzaytoonah private university (Amman, Jordan)	Sep 2014-Present
Visiting Research Scholar, University of Florida (Gainesville, Florida)	Aug 2014-May 2015
Post-doctoral Fellow, University of New Mexico (Albuquerque, New Mexico)	Sep 2013- July 2014
Teaching Assistant, Virginia Commonwealth University (Richmond, Virginia)	Aug 2007- May 2008 Aug 2009- May 2010
Pharmacy Skills Lab (1 Semester) Biostatistical Methods I & II (3 Semesters)	
Hospital Pharmacist, King Hussein Cancer Center (Amman, Jordan)	May 2004- July 2005
Inpatient, outpatient and chemotherapy pharmacies	
Chief Pharmacist, Malhas Hospital (Amman, Jordan)	Sep 2002- April 2004
Retail Pharmacist, Several Retail Pharmacies (Amman, Jordan)	Aug 2000- Aug 2004
Teaching Assistant (Laboratory Instructor) School of Pharmacy, University of Jordan (Amman, Jordan)	Sep 2000- June 2002

Relevant Graduate Course Work: GPA 4.00

Biostatistical Methods I and II	Epidemiology I and II
Applied Statistics I and II	Clinical Epidemiology
Applied Linear Regression	Pharmacoepidemiology
Advanced Regression	Clinical Trials
Multivariate Analysis	Biostatistical Computing
Analysis of Biomedical Data	Advanced Pharmacotherapy Research Methods

Computer Skills

SAS, JMP, Microsoft Office

Research Interests

Infectious diseases, Design and analysis of pharmacoepidemiology studies

Memberships

Jordan Pharmaceutical Association

Peer-Reviewed Publications

Dilworth TJ, **Ibrahim OM**, Mercier RC. Impact of an intravenous trimethoprim/sulfamethoxazole shortage on treatment outcomes among HIV-infected patients with *Pneumocystis jirovecii* pneumonia. *J Manag Care Spec Pharm*. 2014 Dec;20(12):1246-54.

Ibrahim OM, Dilworth TJ, Mercier RC. Reply to "Probability of eradication using vancomycin alone or in combination for methicillin-resistant *Staphylococcus aureus* bacteremia". *Antimicrob Agents Chemother*. 2014 Dec;58(12):7618-9.

Ibrahim OM, Polk RE. Antimicrobial use metrics and benchmarking to improve stewardship outcomes: methodology, opportunities, and challenges. *Infect Dis Clin North Am*. 2014 Jun;28(2):195-214

Dilworth TJ, **Ibrahim O**, Hall P, Sliwinski J, Walraven C, Mercier RC. β -Lactams enhance vancomycin activity against methicillin-resistant *Staphylococcus aureus* bacteremia compared to vancomycin alone. *Antimicrob Agents Chemother* 58(1):102-9 (2014).

Ibrahim OM, Polk RE. Benchmarking antimicrobial drug use in hospitals. *Expert Rev Anti Infect Ther* 10(4):445-57 (2012).

Polk RE, Hohmann SF, Medvedev S, **Ibrahim O**. Benchmarking Risk-Adjusted Adult Antibacterial Drug Use in 70 US Academic Medical Center Hospitals. *Clin Infect Dis* 53(11), 1100-1110 (2011).

Pakyz AL, Gurgle HE, **Ibrahim OM**, Oinonen MJ, Polk RE. Trends in antibacterial use in

pediatric patients in United States academic health centers. Infect Control Hosp Epidemiol 30(6):600-3 (2009).

Presentations at National Meetings

Development of a Risk-adjusted Model to Benchmark Antibacterial Drug Use in the University Health System Consortium Hospitals

Annual Infectious Diseases Pharmacotherapy Fellowship Forum Aspen, CO May 20-23 2010

Honors and Awards

Fullbright Student (Pre-doctoral) Scholarship	Aug 2005-July 2007
Phi Kappa Phi Honor Society, Academic Excellence Award (Masters)	2008